(Q37765050)

22 August 2017

1 reference

title

Future perspectives in hepatocellular carcinoma (English)

1 reference

22 August 2017

Marcus A Wörns

1

1 reference

22 August 2017

Peter R Galle

series ordinal

2

1 reference

22 August 2017

publication date

1 July 2010

1 reference

Digestive and Liver Disease

22 August 2017

published in

1 reference

22 August 2017

volume

42 Suppl 3

1 reference

22 August 2017

page(s)

S302-9

1 reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Novel advancements in the management of hepatocellular carcinoma in 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Recurrence of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Molecular targeted therapies in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Genomics and signaling pathways in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

mTOR inhibitors for hepatocellular cancer: a forward-moving target

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Systemic therapies in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

New drugs for the treatment of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960521-X

7 January 2021

10.1016/S1590-8658(10)60521-X

Identifiers

DOI

1 reference

22 August 2017

1 reference